Sat.Aug 10, 2024

article thumbnail

Finerenone Significantly Reduces Cardiovascular Death, Heart Failure in the FINEARTS-HF Trial

Pharmacy Times

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

article thumbnail

Andelyn Biosciences and Broad Institute of MIT Enter into License Agreement to include MyoAAV Plasmids in AAV Platform

PharmaTech

With the agreement, Andelyin Biosciences will add MyoAAV plasmids developed by Broad Institute of MIT and Harvard to its AAV Curator Platform.

52
article thumbnail

FDA Grants Rare Pediatric Disease Designation to SAT-3247 to Treat Duchenne Muscular Dystrophy

Pharmacy Times

The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.

FDA 55